Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

Zamarin, Dmitriy; A. Burger, Robert; W. Sill, Michael; J. Powell, Daniel; A. Lankes, Heather; D. Feldman, Michael; Zivanovic, Oliver; C. Gunderson, Camille; Ko, Emily; Mathews, Cara; Sharma, Sudarshan; R. Hagemann, Andrea; N. Khleif, Samir; Aghajanian, Carol

doi:10.1200/jco.19.02059

Public

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

Published in Journal of Clinical Oncology • Apr 10, 2020

Authors:

Dmitriy Zamarin

Robert A. Burger

Michael W. Sill

Abstract

PURPOSE Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent EOC. METHODS Eligibility criteria included measurable disease, 1-3 prior regimens, and platinum-...

Subject

Nivolumab

Medicine

Ipilimumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!